メディサイエンスプラニング
メディサイエンスプラニング, also known as MPI, is a prominent contract research organisation (CRO) headquartered in Japan. Established in 2000, the company has made significant strides in the pharmaceutical and biotechnology sectors, providing comprehensive clinical trial services across Asia and beyond. Specialising in clinical development, regulatory affairs, and data management, メディサイエンスプラニング distinguishes itself through its commitment to quality and innovation. The company has successfully facilitated numerous clinical trials, contributing to the advancement of medical research and drug development. With a strong market position, メディサイエンスプラニング has garnered recognition for its expertise and reliability, making it a trusted partner for global pharmaceutical companies. Its dedication to excellence continues to drive its growth and influence within the industry.
DitchCarbon Score
How does メディサイエンスプラニング's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Business Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
メディサイエンスプラニング's score of 16 is higher than 78% of the industry. This can give you a sense of how well the company is doing compared to its peers.
メディサイエンスプラニング's reported carbon emissions
In 2023, メディサイエンスプラニング reported total carbon emissions of approximately 3,887,790,000 kg CO2e, with emissions distributed across all three scopes. Specifically, Scope 1 emissions were about 85,245,000 kg CO2e, Scope 2 emissions totalled approximately 23,994,000 kg CO2e, and Scope 3 emissions accounted for around 3,778,790,000 kg CO2e. Comparatively, in 2022, the company recorded total emissions of about 1,809,230,000 kg CO2e, with Scope 1 at approximately 86,006,000 kg CO2e, Scope 2 at around 23,729,000 kg CO2e, and Scope 3 emissions significantly higher at about 1,800,000,000 kg CO2e. The 2021 figures show a total of approximately 682,000,000 kg CO2e, with Scope 1 emissions at about 88,249,000 kg CO2e, Scope 2 at around 103,150,000 kg CO2e, and Scope 3 at approximately 513,874,000 kg CO2e. Despite these figures, there are currently no disclosed reduction targets or climate pledges from メディサイエンスプラニング. The company operates within a challenging industry context, where significant emissions are often associated with extensive supply chains and operational activities. As such, the absence of specific reduction initiatives highlights an area for potential improvement in their climate strategy.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 88,249,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 103,150,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 513,874,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
メディサイエンスプラニング is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
